OSR Holdings and SillaJen have entered into a Memorandum of Understanding to collaboratively pursue the development of innovative therapeutics and enter the U.S. market
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 22 2024
0mins
Source: PRnewswire
- OSR Holdings and SillaJen Collaboration: OSR Holdings, a healthcare holding company, signed an MOU with SillaJen, a biotech firm, to collaborate on technology sharing and clinical development resources.
- Business Model of OSR Holdings: OSR Holdings follows a "hub-and-spoke" model, allowing centralized management for drug development strategies and resource allocation while subsidiaries focus on new drug assets and innovations.
- Portfolio of OSR Holdings: OSR Holdings' portfolio includes Vaximm AG, Darnatein, and RMC, focusing on immuno-oncology therapeutics, osteoarthritis drugs, and medical devices respectively.
- SillaJen's Drug Pipeline: SillaJen has a diverse pipeline including the SJ-600 series and BAL0891, developing anti-cancer viruses based on its GEEV® platform.
- Future Plans: Both companies aim to become strategic partners in global immuno-oncology markets, exploring opportunities for collaboration, particularly in the U.S. pharmaceutical market.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
